Q2 FY27 revenue up 25%, PAT up 22%; H1 PAT up 31% with wider margins
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.8 pts less than Nifty Microcap 250 and 8.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 FY27 revenue was Rs 192.33 crore, up 25% year on year, and PAT was Rs 36.60 crore, up 22%. H1 revenue rose 30% to Rs 372.54 crore and PAT rose 31% to Rs 67.05 crore. H1 EBITDA was Rs 111 crore, up 58%, with about 530 basis points margin expansion. Operating cash flow was positive. The review report flags an emphasis of matter on management-estimated tax and deferred tax. Talati and Talati LLP joins as joint statutory auditor.
Revenue and PAT rose with wider margins. Management targets 30-40% revenue and 50-60% PAT growth in FY27. Tax estimates are a watch point.